drugset / Trial / NCT03630952
Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this clinical study is to evaluate the efficacy and safety of two different levels of conbercept intravitreal (IVT) injection as compared to the approved vascular endothelial growth factor (VEGF) antagonist active control, aflibercept intravitreal injection (2.0 mg/eye, Eylea®), in subjects with neovascular AMD.
Timeline
- Start
- 2018-12-21
- Primary completion
- 2020-09-10
- Completion
- 2021-05-19
Outcome
Outcome not reported
Stopped: “desired primary endpoint was not met”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aflibercept | Protein / enzyme biologic | 2 mg | Intravitreal |
| Subject | Conbercept | Protein / enzyme biologic | 0.5 mg | Intravitreal |
| Subject | Conbercept | Protein / enzyme biologic | 1 mg | Intravitreal |